Neola Medical

Neola Medical Current Assets

The Current Assets of Neola Medical (NEOLA.ST) as of Oct 21, 2026 is 16.12 M SEK. In the previous year, Current Assets was 18.57 M SEK — a change of -13.17% (lower).

Current Assets

16.12 MSEK

YoY

-13.17%

Last updated:

Current Assets of Neola Medical is 2025 16.12 M SEK. Current Assets of Neola Medical was 2024 18.57 M SEK. It decreases by -13.17% lower compared to the previous year.

The Neola Medical Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
9.86 M SEK
Jan 1, 2019
5.85 M SEK
Jan 1, 2020
16.86 M SEK
Jan 1, 2021
23.34 M SEK
Jan 1, 2022
40.58 M SEK
Jan 1, 2023
22.21 M SEK
Jan 1, 2024
18.57 M SEK
Jan 1, 2025
16.12 M SEK
The Neola Medical Current Assets history
YEARCurrent AssetsYoY
16.12 MSEK-13.17%
18.57 MSEK-16.39%
22.21 MSEK-45.27%
40.58 MSEK+73.89%
23.34 MSEK+38.40%
16.86 MSEK+188.09%
5.85 MSEK-40.64%
9.86 MSEK-16.00%
11.74 MSEK-25.77%
15.81 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neola Medical Stock analysis

What does Neola Medical do? Neola Medical AB commercializes medical devices based on its patented GASMAS technology for continuous lung monitoring in premature babies. The company's primary product, NEOLA, provides real-time alerts for life-threatening complications by measuring lung volume changes and oxygen concentration. Neola Medical targets neonatal intensive care units as its key market segment, serving healthcare providers who require advanced monitoring solutions for premature infants. The firm's revenue model relies on selling the NEOLA device and associated technology to hospitals and medical facilities specializing in neonatal care. The company's business concept centers on the commercialization of its medical technology product for continuous lung monitoring, leveraging the GASMAS (Gas in Scattering Media Absorption Spectroscopy) technology. Neola Medical focuses on the neonatal intensive care market segment, where its device offers continuous monitoring capabilities that address critical needs in premature infant care. The primary purpose of the NEOLA device is to support neonatal intensive care through real-time monitoring and alerts for complications. Neola Medical AB's revenue streams come from the sale of the NEOLA medical device and its underlying technology to healthcare institutions. The company targets neonatal intensive care units as its primary customer segment, focusing on hospitals and medical facilities that provide specialized care for premature babies. The firm's business model is built around the commercialization of its patented GASMAS technology through the NEOLA device, which addresses specific monitoring needs in neonatal care. Neola Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neola Medical stock

Current Assets of Neola Medical is 16.12 M SEK in 2025.

Current Assets of Neola Medical changed from 18.57 M SEK to 16.12 M SEK, representing a -13.17% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Neola Medical since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Neola Medical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Neola Medical

All Key Metrics — Neola Medical